KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Operating Expenses: 2009-2025

Historic Operating Expenses for Arbutus Biopharma (ABUS) over the last 16 years, with Sep 2025 value amounting to $9.2 million.

  • Arbutus Biopharma's Operating Expenses fell 59.66% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.4 million, marking a year-over-year decrease of 31.67%. This contributed to the annual value of $82.5 million for FY2024, which is 14.29% down from last year.
  • Arbutus Biopharma's Operating Expenses amounted to $9.2 million in Q3 2025, which was down 0.68% from $9.3 million recorded in Q2 2025.
  • Over the past 5 years, Arbutus Biopharma's Operating Expenses peaked at $28.8 million during Q4 2022, and registered a low of $9.2 million during Q3 2025.
  • Moreover, its 3-year median value for Operating Expenses was $22.9 million (2023), whereas its average is $20.4 million.
  • In the last 5 years, Arbutus Biopharma's Operating Expenses spiked by 43.10% in 2021 and then tumbled by 60.31% in 2025.
  • Over the past 5 years, Arbutus Biopharma's Operating Expenses (Quarterly) stood at $24.0 million in 2021, then increased by 20.02% to $28.8 million in 2022, then fell by 20.53% to $22.9 million in 2023, then plummeted by 32.26% to $15.5 million in 2024, then slumped by 59.66% to $9.2 million in 2025.
  • Its last three reported values are $9.2 million in Q3 2025, $9.3 million for Q2 2025, and $27.5 million during Q1 2025.